Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.45 |
| ▸ | GRM5 | P41594 | 6/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19284582 | 0.89 | PDK4 (0.56) | PDK4HTR6SCN9AJAK1CNR1 | |
| SCHEMBL19284633 | 0.88 | PDK4 (0.61) | PDK4HTR6SCN9AJAK1CNR1 | |
| SCHEMBL6808096 | 0.86 | PDK4 (0.59) | PDK4HTR6SCN9AJAK1CNR1 | |
| SCHEMBL6847847 | 0.85 | PDK4 (0.69) | PDK4HTR6SCN9AJAK1CNR1 | |
| SCHEMBL6808255 | 0.84 | HTR1D (0.48) | PDK4HTR1DHTR1B | |
| SCHEMBL31747276 | 0.81 | PDK4 (0.54) | PDK4HTR6JAK1GRM1GRM5 | |
| SCHEMBL19297116 | 0.80 | PDK4 (0.59) | PDK4HTR6JAK1CNR1GRM1 | |
| SCHEMBL31110456 | 0.79 | NAMPT (0.58) | PDK4HTR6SCN9AGRM1GRM5 | |
| SCHEMBL31414517 | 0.79 | PDK4 (0.56) | PDK4HTR6SCN9AJAK1CNR1 | |
| SCHEMBL19284578 | 0.79 | PDK4 (0.65) | PDK4HTR6SCN9AJAK1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | PDK4 3535/4885HTR6 863/4885SCN9A 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.